Improving uptake of Fracture Prevention drug Treatments (iFraP)

  • Research type

    Research Study

  • Full title

    A person-centred approach to improving uptake of Fracture Prevention drug Treatments (iFraP): a randomised controlled trial of the iFraP intervention in Fracture Liaison Services [Patient facing title: Being informed and involved: Improving appointments about your bone health]

  • IRAS ID

    315303

  • Contact name

    Zoe Paskins

  • Contact email

    z.paskins@keele.ac.uk

  • Sponsor organisation

    Keele University

  • ISRCTN Number

    ISRCTN10606407

  • Duration of Study in the UK

    2 years, 0 months, 30 days

  • Research summary

    The iFraP study team have developed a web based visual tool called a ‘decision-support tool’ to support Fracture Liaison Service healthcare professionals to know when to suggest treatments and aid conversations with patients about risk and to make decisions, for instance about starting osteoporosis medicines. The team have also developed training for healthcare professionals to help them use the tool and to ensure that the information they are giving is understandable, that they address patient concerns, and that they give clear, consistent information during the appointment. The decision-support tool and training package together are called the ‘iFraP intervention’.
    The iFraP study will look at whether the iFraP intervention makes decision making about osteoporosis medicines easier, and whether it is cost-effective, acceptable and practical to deliver.
    328 participants will be recruited to this study; these will be adults aged 50 years and older who have been referred to a Fracture Liaison Service. Study participants will be allocated to receive one of two options: usual NHS care or the iFraP intervention. Everyone who takes part in the study will receive best current NHS practice in their Fracture Liaison Service appointment.
    Participants will be asked to complete 3 questionnaires (one at baseline, one at 2 weeks and one at 3 months after their Fracture Liaison Service appointment) and they will also have the option to have their appointment recorded. A selection of participants will be invited to take part in an interview to find out what they thought of their Fracture Liaison Service appointment. Patients will be involved in the study for a duration of 3 months follow up.

  • REC name

    East of Scotland Research Ethics Service REC 1

  • REC reference

    22/ES/0038

  • Date of REC Opinion

    21 Oct 2022

  • REC opinion

    Further Information Favourable Opinion